Richard S. Finn, MD

Article

Targeted Agents Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Author:: Richard S. Finn, MD

Publish date: April 3, 2023

The use of targeted agents such as PI3K, mTOR, and CDK4/6 inhibitors combined with endocrine therapy (ET) may overcome ET resistance in HR+/HER2- a...